Novartis Says Profit May Drop on Entresto Spending, Gleevec - Bloomberg
BloombergNovartis Says Profit May Drop on Entresto Spending, GleevecBloombergNovartis AG said profit may fall this year as the Swiss drugmaker increases spending on the heart medicine Entresto and faces declining sales of its best-selling cancer treatment Gleevec.
Right To Health, Colombia And US Congress - Huffington Post
Huffington PostRight To Health, Colombia And US CongressHuffington PostRecent memos allegedly leaked from the Colombian Embassy in Washington describe intense pressure by the pharmaceutical industry and its Congressional allies to discourage Colombia's efforts to half the local price of Novartis' Gleevec, one of the .
Grassley looking into Medicare drug 'exploitation' - Chronicle-Telegram
Grassley looking into Medicare drug 'exploitation'Chronicle-TelegramGleevec, a breakthrough drug introduced in 2001 to treat leukemia, was ensconced as fifth among the top 10 pricey medications, with more than $1 billion spent in 2015.
Novartis erwartet weniger Gewinn wegen Entresto-/Gleevec-Kosten - DIE WELT
Credit Suisse Prescribes Underperform Rating For Dr. Reddy's With Drop In U.S. Sales - Benzinga
Credit Suisse Prescribes Underperform Rating For Dr.